Roche’s Genentech Expands Immuno-Oncology Collaboration with Bicycle Therapeutics to Develop Novel Bicycle-Based Therapies

October 26, 2021 /BioonBIOON/ --Bicycle Therapeutics recently announced that Genentech, a member of the Roche Group, has exercised its option to initiate a new program, expanding its exclusive strategic collaboration agreement with Bicycle Therapeutics to discover, develop, and commercializeBicycle-Based Novel ImmunotherapyTumorTherapy。

Bicycle Therapeutics and Genentech are collaborating on the discovery and preclinical development of novel Bicycle-based immunotherapies targeting multiple targets. Under the terms of the February 2020 agreement, Genentech has exercised its option to include a new program under the agreement, resulting in a $10 million payment to Bicycle Therapeutics. Any compounds in Bicycle Therapeutics' wholly owned oncology pipeline, including its immuno-Tumorcandidate drugs are not included within the scope of the collaboration.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of therapeutics, known as Bicycles, for the treatment of diseases that are currently untreatable with existing therapies.Bicycle is a fully synthetic short peptide constrained by a small-molecule scaffold, forming two loops that stabilize its structural conformation. This constraint facilitates target binding with high affinity and selectivity, making Bicycle an attractive candidate for drug development.

Currently, Bicycle Therapeutics is evaluatingBT5528, this is a second-generation EphA2-targeting Bicycle toxin conjugate (BTC), in Phase 1/2Clinical Trials. The company is also evaluatingBT8009, which is a second-generation Nectin-4-targeted BTC, currently in Phase 1/2Clinical Trial, Nectin-4 is a well-validatedTumorAntigen. In addition, the company is also evaluatingBT1718, a BTC targeting MT1-MMP, in Phase 1/2aClinical Trial。

Dr. Kevin Lee, Chief Executive Officer of Bicycle Therapeutics, said: “We are pleased with the progress achieved in our current collaboration with Genentech, and with Genentech’s decision to add a new program under the collaboration. We believe that the expansion of our partnership, compared to other modalities, highlights the potential utility of Bicycle® technology, as well as its potential broad applicability across a wide range of targets. We look forward to continuing to work with Genentech’s outstanding immunologyTumorcollaborate closely with the research team to develop potential new cancer therapies based on Bicycle® technology.” (Bioon.com)

Original Source:Bicycle Therapeutics Announces Expansion of Genentech Immuno-Oncology Collaboration